Engineering CAR-T Cells for Next-Generation Cancer Therapy

Area of Science:

• Immunology
• Cell Therapy
• Oncology

Background:

• Chimeric antigen receptor (CAR)-T cell therapy has revolutionized hematologic malignancy treatment.
• Broader applications require enhanced efficacy and safety, particularly for solid tumors.
• The tumor microenvironment (TME) presents significant biological challenges for CAR-T cells.

Purpose of the Study:

• To review recent engineering strategies for improving CAR-T cell therapy.
• To address challenges in applying CAR-T cells to solid tumors.
• To highlight advancements in CAR protein, T cell, and TME interaction engineering.

Main Methods:

• Review of recent scientific literature on CAR-T cell engineering.
• Analysis of strategies targeting CAR protein modifications.
• Examination of T cell intrinsic modifications and TME interaction modulation.

Main Results:

• Engineering the CAR protein can improve target recognition and signaling.
• Modifications to T cells can enhance their persistence and function within the TME.
• Strategies to modulate TME interactions are crucial for overcoming tumor resistance.

Conclusions:

• Multi-level engineering of CAR-T cells is essential for broader therapeutic success.
• Overcoming solid tumor challenges requires sophisticated approaches to CAR design and T cell function.
• Future directions involve integrating these engineering strategies for improved CAR-T cell therapy.